Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company PRINCETON, N.J., Jan. 22, 2024 ...
PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results